# Lentiviral Gene Transfer to iPS Cells: Toward the Cardiomyocyte Differentiation of Pompe Disease-Specific iPS Cells

48

Yohei Sato, Takashi Higuchi, Hiroshi Kobayashi, Susumu Minamisawa, Hiroyuki Ida, and Toya Ohashi

## **Keywords**

iPS cells • Lentivirus • Pompe disease

Pompe disease is an inherited neuromuscular disorder caused by a genetic deficiency of acid-glucosidase-alpha (GAA). The clinical symptoms of Pompe disease include progressive weakness, respiratory failure, and ventricular hypertrophy. Enzyme replacement therapy has been shown to ameliorate these symptoms. Cardiomyocytes derived from patient/disease-specific iPS cells (iPS-CMs) have been used for pathophysiological analyses, drug screening, and cell therapy. Our research goal was to generate cardiomyocytes that can be differentiated from gene-corrected Pompe disease-specific iPS cells.

We obtained iPSC (TkDA3-4) generated from human dermal fibroblasts [1]. GAA was cloned into cDNA expressing third-generation lentiviral vectors (CS2-EF1 $\alpha$ -GAA). To assess the transfection efficacy, Venus, a YFP variant protein, was also cloned into the vector (CS2-EF1 $\alpha$ -Venus). Then, we transfected lentiviral vectors containing GAA to iPSCs at three different concentrations to

Department of Gene Therapy, Jikei University School of Medicine, 3-25-8 Nishishimbashi Minato-ku, Tokyo, Japan

e-mail: yoheisato@jikei.ac.jp

#### T. Higuchi

Department of Gene Therapy, Jikei University School of Medicine, 3-25-8 Nishishimbashi Minato-ku, Tokyo, Japan

### S. Minamisawa

Department of Cell Physiology, Jikei University School of Medicine, 3-25-8 Nishishimbashi Minato-ku, Tokyo, Japan

Y. Sato ( ) • H. Kobayashi • H. Ida • T. Ohashi

Department of Pediatrics, Jikei University School of Medicine, 3-25-8 Nishishimbashi Minato-ku, Tokyo, Japan

<sup>©</sup> The Author(s) 2016

342 Y. Sato et al.




Fig. 48.1 Gene transfer to HEK293A cells and TkDA3-4. Dose-dependent expressions of GAA and Venus were observed in each cell line

determine the optimized titer for gene correction. We showed that dose-dependent expression of both GAA and Venus was observed in iPSCs, even though the expression levels were relatively low compared to HEK293A cells.

Cardiomyocyte differentiation of iPS cells is the most important procedure for replicating the disease hallmarks of Pompe disease. In fact, there is no single best protocol for obtaining cardiomyocytes derived from iPS cells. The functional assessment of iPSC-derived cardiomyocytes is another critical aspect of our research. The differences between the function of iPSC-derived cardiomyocytes obtained from normal control cells and those obtained from Pompe disease cells should therefore be strictly evaluated in order to thoroughly discuss the efficacy of gene therapy for iPSC (Fig. 48.1).

**Acknowledgments** The author thanks Dr. M. Otsu at Tokyo University for providing iPSC TkDA3-4 cell lines. Third-generation lentiviral vector was a kind gift from Dr. H. Miyoshi at RIKEN BRC, and Venus was kindly provided from A. Miyawaki at RIKEN BSI.

**Open Access** This chapter is distributed under the terms of the Creative Commons Attribution-Noncommercial 2.5 License (http://creativecommons.org/licenses/by-nc/2.5/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

The images or other third party material in this chapter are included in the work's Creative Commons license, unless indicated otherwise in the credit line; if such material is not included in the work's Creative Commons license and the respective action is not permitted by statutory regulation, users will need to obtain permission from the license holder to duplicate, adapt or reproduce the material.

## Reference

 Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med. 2010;207(13):2817–30.